drugset / Trial / NCT06045689
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Timeline
- Start
- 2023-10-05
- Primary completion
- 2025-10-01
- Completion
- 2027-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luspatercept | Protein / enzyme biologic | — | — |